Results in the 45 mg BID group found a 54% decrease from baseline in the rate of level one hypoglycemia, 57% for the rate of level two hypoglycemia, and 68% for the rate of level three severe hypoglycemia
[10] The suggestion that it preserves physiological feedback regulation is a reasonable mechanistic concept, but clinical outcome superiority over licensed recombinant human GH (somatropin) has not been established
En l'absence d'essais cliniques de phase I/II/III achevs et publis, il est impossible de dresser un profil complet des effets indsirables potentiels chez l'humain
DCCT/EDIC Research Group, Nathan DM, Bebu I, Hainsworth D, Klein R, Tamborlane W, et al
doi:10.1590/1516-4446-2013-1154 103 zcan, D